Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17795772 | 1.00 | TDP1 (0.36) | TDP1ALDH1A1TSHRGBA1GABRP | |
| SCHEMBL5076199 | 1.00 | TDP1 (0.36) | TDP1ALDH1A1TSHRGBA1GABRP | |
| SCHEMBL4648895 | 1.00 | TDP1 (0.36) | TDP1ALDH1A1TSHRGBA1GABRP | |
| SCHEMBL204261 | 1.00 | TDP1 (0.36) | TDP1ALDH1A1TSHRGBA1GABRP | |
| Hydrochloric Acid SCHEMBL143429 | 0.98 | TDP1 (0.39) | TDP1ALDH1A1TSHRGBA1GABRP | |
| SCHEMBL10076954 | 0.84 | GBA1 (0.31) | TDP1GBA1 | |
| SCHEMBL21515903 | 0.84 | GBA1 (0.31) | TDP1GBA1 | |
| SCHEMBL21514826 | 0.84 | GBA1 (0.31) | TDP1GBA1 | |
| SCHEMBL16845501 | 0.82 | SMN1; SMN2 (0.35) | GBA1SMN1; SMN2 | |
| SCHEMBL26431341 | 0.82 | GBA1 (0.30) | TSHRGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005065675-A1 | METHOD OF TREATMENT | PREMACS INTERNATIONAL PTY. LTD. (AU) | 2005-07-21 | — | — | WO | claimed |
| WO-2023214576-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| US-20080125319-A1 | Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield | MONSANTO TECHNOLOGY, LLC (US) | 2008-05-29 | — | — | US | disclosed |
| EP-1711462-A1 | PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS | Salama, Zoser B. nat.rer.Dr. (DE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005065675-A1 | METHOD OF TREATMENT | PREMACS INTERNATIONAL PTY. LTD. (AU) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005058816-A1 | PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS | SALAMA ZOSER B (DE) | 2005-06-30 | — | — | WO | disclosed |
| US-20040259732-A1 | Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield | MONSANTO TECHNOLOGY, L.L.C. | 2004-12-23 | — | — | US | disclosed |
| WO-2004095926-A2 | TREATMENT OF PLANTS AND PLANT PROPAGATION MATERIALS WITH AN ANTIOXIDANT TO IMPROVE PLANT HEALTH AND/OR YIELD | MONSANTO TECHNOLOGY, LLC (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1188055-B1 | LABORATORY EXAMINATION OF A BODY FLUID OR TISSUE SAMPLE | HOERRMANN WILHELM (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1188055-A2 | LABORATORY EXAMINATION OF A BODY FLUID OR TISSUE SAMPLE | Hoerrmann, Wilhelm, Dr. (DE) | 2002-03-20 | — | — | EP | disclosed |
| CN-1275051-A | Method for improving the freezing tolerance of plant | UNIV DU QUEBEC A MONTREAL (CA) | 2000-11-29 | — | — | CN | disclosed |
| WO-2000067022-A2 | LABORATORY EXAMINATION OF A BODY FLUID OR TISSUE SAMPLE | HOERRMANN WILHELM (DE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | TDP1 2885/4885ALDH1A1 1543/4885TSHR 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.